Wells Fargo Downgrades Dimension Therapeutics (DMTX) to Market Perform Following Proposed Acquisition
Tweet
Share
E-mailGet Alerts DMTX Hot Sheet
Price: $5.95 --0%
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
2 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wells Fargo downgraded Dimension Therapeutics (NASDAQ: DMTX) from Outperform to Market Perform with a price target of $6.00.
The analyst expects the proposal to be consummated and low likelihood that a competing offer will emerge.
For an analyst ratings summary and ratings history on Dimension Therapeutics click here. For more ratings news on Dimension Therapeutics click here.
Shares of Dimension Therapeutics closed at $5.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Downgrades Roku Inc. (ROKU) to Equal Weight
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
